Functional Testosterone Deficiency in Aging Men: Clinical Impact, Diagnostic Pathways, and Treatment Strategies

Review of current evidence finds aging alone doesn't cause low T — obesity and diabetes do, and recent RCTs report no added cardiovascular risk from treatment

Journal: Maturitas | Published: 2026-02-06 | Type: Review | PMID: 41655564 Authors: Zitzmann M, Soave A, Bier S (Centre for Reproductive Medicine and Andrology, University Hospital Münster; Dept. of Andrology, University Hospital Hamburg-Eppendorf) Funding/COI: Funding not disclosed. Authors declare no competing interests.

Summary

This narrative review argues that "functional hypogonadism" — low testosterone driven by obesity, type 2 diabetes, and metabolic syndrome rather than primary testicular or pituitary failure — is distinct from age-related decline, and that aging per se does not cause hypogonadism. The authors synthesize evidence from recent large-scale RCTs and observational data to argue that guideline-directed testosterone therapy is both safe and metabolically beneficial when patients are properly selected. The cardiovascular safety claim leans heavily on a small number of recent trials, particularly TRAVERSE.

Claims

• Aging alone does not precipitate hypogonadism; age-associated comorbidities (obesity, T2DM) are the proximate cause of functional hypogonadism
• Functional hypogonadism and metabolic syndrome share a bidirectional relationship — each worsens the other — and both are associated with increased cardiovascular mortality
• Manifestations include depression, fatigue, cognitive decline, reduced libido, erectile dysfunction, visceral fat accumulation, sarcopenia, osteopenia/osteoporosis, and anemia
• Testosterone therapy, per recent large-scale RCTs, does not increase cardiovascular risk or mortality
• Treatment is reported to improve sexual function, mood, muscle mass, bone density, anemia, and metabolic parameters
• Contraindications include active prostate carcinoma and current fertility intention; hematocrit and prostate health require monitoring

Study Quality

This is a narrative review, not a systematic review or meta-analysis — meaning the authors selected the evidence rather than exhaustively cataloguing it. No PRISMA flowchart, no formal quality scoring of included studies, no pre-registered protocol. The abstract references "recent randomized trials and large-scale observational studies" without naming them, which makes independent verification of the evidence base impossible from the abstract alone. The cardiovascular safety conclusion specifically appears to rest on TRAVERSE (Lincoff et al., 2023, N=5,246), a trial with its own limitations including enrichment for cardiovascular risk and industry involvement, though that trial is not cited here explicitly.

The claim that aging per se does not cause hypogonadism is a legitimate and increasingly accepted distinction in the field, but a narrative review is a weak vehicle for settling it. The authors are experienced andrologists at major European centres, which lends clinical credibility, but also means they have strong prior views.

Red Flags

• Narrative review format allows cherry-picking — no explicit search strategy or inclusion criteria stated
• Funding not disclosed; for a review this favorable toward testosterone therapy, that omission is notable
• Sweeping safety claims ("does not augment cardiovascular risk or mortality") stated as conclusions rather than probabilistic findings — this overstates what any single trial can establish
• Abstract language is unusually ornate ("somatic derangements," "psychosocial sequelae," "therapeutic armamentarium") — a stylistic flag that can obscure imprecision in underlying claims
• No specific effect sizes or study names in the abstract; published in Maturitas, not a top-tier endocrinology journal

Strengths

• Addresses functional hypogonadism as a distinct clinical entity — a useful conceptual framing often lost in general "low T" discourse
• Authors have institutional credibility in andrology (Münster, Hamburg-Eppendorf)
• Covers the full clinical picture: diagnosis, pathophysiology, treatment, monitoring, contraindications
• No declared conflicts of interest, which at minimum eliminates direct pharma funding disclosure concerns

Verdict

A useful clinical overview from experienced andrologists, but the review format limits its evidentiary weight. The core argument — that functional hypogonadism is a metabolic disease masquerading as aging, and that treating it is safe — is increasingly mainstream, but the abstract makes it sound more settled than the evidence warrants. The lack of disclosed funding is notable given the field's history of manufacturer-sponsored literature. Read it as expert opinion synthesizing current practice, not as a definitive safety verdict on testosterone therapy.